SI-BONE (NASDAQ:SIBN – Get Free Report) and Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Profitability
This table compares SI-BONE and Tactile Systems Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SI-BONE | -29.93% | -25.14% | -18.77% |
| Tactile Systems Technology | 10.19% | 15.88% | 10.33% |
Volatility & Risk
SI-BONE has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SI-BONE | $138.89 million | 4.55 | -$43.34 million | ($1.09) | -14.05 |
| Tactile Systems Technology | $276.67 million | 1.03 | $28.51 million | $1.20 | 10.02 |
Tactile Systems Technology has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for SI-BONE and Tactile Systems Technology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SI-BONE | 0 | 0 | 6 | 0 | 3.00 |
| Tactile Systems Technology | 0 | 0 | 1 | 0 | 3.00 |
SI-BONE currently has a consensus price target of $26.33, indicating a potential upside of 71.89%. Tactile Systems Technology has a consensus price target of $30.00, indicating a potential upside of 149.58%. Given Tactile Systems Technology’s higher possible upside, analysts clearly believe Tactile Systems Technology is more favorable than SI-BONE.
Insider and Institutional Ownership
98.1% of SI-BONE shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 5.4% of SI-BONE shares are held by company insiders. Comparatively, 1.0% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Tactile Systems Technology beats SI-BONE on 8 of the 13 factors compared between the two stocks.
About SI-BONE
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
About Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.
